Hereditary angioedema with normal C1 inhibitor: Update on evaluation and treatment

by mm-red | Jun 21, 2020

Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study

by mm-red | Jun 13, 2020

Background: Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1-INH- HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small mole- cule inhibitor of...

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

by mm-red | Jun 9, 2020

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of...

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

by mm-red | Jun 9, 2020

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of...

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe

by mm-red | Jun 5, 2020

Background: Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease characterized by recurrent edema attacks. Important advances in HAE treatment have been made, including the development of new therapies for treating or...